2Shao DD, Xue W, Krall EB, et al. KRAS and YAP 1 con- verge to regulate EMT and tumor survival[J]. Cell, 2014, 158(1): 171-184.
3Lei QY, Zhang H, Zhao B, et al. TAZ promotes cell prolifer- ation and epithelial-mesenchymal transition and is inhibited by the hippo pathway[J]. Mol Cell Biol, 2008, 28(7): 2426- 2436.
4Justice RW, Zilian O, Woods DF, et al. The Drosophila tu- mor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation [J]. Genes Dev, 1995, 9(5): 534-546.
5Johnson R, Halder G. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treat- ment[J]. Nat Rev Drug Discov, 2014, 13(1): 63-79.
6Hau JC, Erdmann D, Mesrouze Y, et al. The TEAD4-YAP/ TAZ protein-protein interaction: expected similarities and unexpected differences[J]. Chembiochem, 2013, 14(10): 1218-1225.
7Zhao B, Tumaneng K, Guan KL. The Hippo pathway in or-gan size control, tissue regeneration and stem cell self-re- newal[J]. Nat Cell Biol, 2011, 13(8): 877-883.
8Cordenonsi M, Zanconato F, Azzolin L, et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells[J]. Cell, 2011, 147(4): 759-772.
9Muramatsu T, Imoto I, Matsui T, et al. YAP is a candidate oncogene for esophageal squamous cell carcinoma[J]. Car- cino~enesis, 2011, 32(3): 389-398.
10Noguchi S, Saito A, Horie M, et al. An integrative analy- sis of the tumorigenic role of TAZ in human non-small cell lung cancer[J]. Clin Cancer Res, 2014, 20(17): 4660- 4672.